Anatomical outcome after brachytherapy with bi-nuclide (Ru-106/Iodine-125) plaques in large uveal melanomas.

Cohort studyRadiation oncology (London, England)· Jul 2025

Anatomical outcome after brachytherapy with bi-nuclide (Ru-106/Iodine-125) plaques in large uveal melanomas.

Leyla Jabbarli, Miltiadis Fiorentzis, Maja Guberina … Nikolaos E Bechrakis

Read paper

Ocular OncologyCohort studyTreatmentQ1IF 3.7

Bi-nuclide plaque brachytherapy retained the eye in 86.5% of large uveal melanomas.

Anatomical outcome after brachytherapy with bi-nuclide (Ru-106/Iodine-125) plaques in large uveal melanomas.

Leyla Jabbarli … Nikolaos E Bechrakis

Radiation oncology (London, England) · Jul 2025

Background

Proprietary bi-nuclide plaques combine the radiation properties of beta and gamma brachytherapy and can irradiate a larger target volume compared to ruthenium-plaques.

Purpose

We aimed at analyzing the local tumor control and eye retention probability after brachytherapy with bi-nuclide-plaques.

Methods

All consecutive cases with large uveal melanoma (tumor thickness ≥ 7 mm) treated with brachytherapy with bi-nuclide-plaques at our institution between 01/1999 and 12/2020 were included (n = 576, median follow-up: 30.8 months [interquartile range, IQR: 12.9-57.4]).

n = 576,

86.5%

Results

86.5%

eyes were surgically removed for 13.5%, so most eyes avoided removal

n = 576,

More results

Secondary enucleation (SE) was performed in 13.5% of cases (n = 78) after the median of 20.0 months (IQR: 9.0-34.7) post-brachytherapy with bi-nuclide-plaques.

More results

The overall rate of local tumor recurrence (LR) in the cohort was 8.5% (n = 49) and was diagnosed at the median post-brachytherapy with bi-nuclide-plaques interval of 20.0 months (IQR: 15.6-35.2).

“

Conclusion · 1 of 2

Brachytherapy with bi-nuclide-plaques facilitates eye retention in 86.5% of patients with large uveal melanoma 2.5 years after treatment.

Conclusion · 2 of 2

Patients' baseline, tumor and treatment characteristics were strongly associated with the risk of SE and LR after brachytherapy with bi-nuclide-plaques.

Anatomical outcome after brachytherapy with bi-nuclide (Ru-106/Iodine-125) plaques in large uveal melanomas.

Anatomical outcome after brachytherapy with bi-nuclide (Ru-106/Iodine-125) plaques in large uveal melanomas.

Related papers